KRAS and non-small cell lung carcinoma: The development of anti-EGFR, anti-VEGF, and anti-ALK therapies has been trialed and proven in NSCLC; the therapies targeted ROS1, MET, and BRAF are under study and own enormously potential to cure NSCLC; there are no currently effective therapies for these targets including KRAS, FGFR1, DDR2, and so on [83].